Current and future drug-eluting coronary stent technology

References

• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med.346(23), 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med.349(14), 1315–1323 (2003).
   PubMed Web of Science ®Google Scholar
• Weisz G, Leon MB, Holmes DR Jr et al. Five-year follow-up after sirolimus-eluting stent implanta-tion results of the SIRIUS (Sirolimus-Eluting Stent in de-novo Native Coronary Lesions) trial. J. Am. Coll. Cardiol.53(17), 1488–1497 (2009).
   PubMed Web of Science ®Google Scholar
• Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol.48(1), 193–202 (2006).
   PubMed Web of Science ®Google Scholar
• Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation109(6), 701–705 (2004).
   PubMed Web of Science ®Google Scholar
• Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol.52(5), 333–342 (2008).
   PubMed Web of Science ®Google Scholar
• van der Giessen WJ, Lincoff AM, Schwartz RS et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation94(7), 1690–1697 (1996).
   PubMed Web of Science ®Google Scholar
• Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol.47(1), 175–181 (2006).
   PubMed Web of Science ®Google Scholar
• Virmani R, Liistro F, Stankovic G et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation106(21), 2649–2651 (2002).
   PubMed Web of Science ®Google Scholar
• Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopa-thological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation120(5), 391–399 (2009).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention4(Suppl. C), C7–C10 (2008).
   Google Scholar
• Serruys PW, Ong AT, Piek JJ et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention1(1), 58–65 (2005).
   PubMedGoogle Scholar
• Serruys PW, Ruygrok P, Neuzner J et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention2(3), 286–294 (2006).
   PubMedGoogle Scholar
• Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA299(16), 1903–1913 (2008).
   PubMed Web of Science ®Google Scholar
• Stone GW, Rizvi A, Newman W et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N. Engl. J. Med.362(18), 1663–1674 (2010).
   PubMed Web of Science ®Google Scholar
• Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet375(9710), 201–209 (2010).
   PubMed Web of Science ®Google Scholar
• Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet369(9562), 667–678 (2007).
   PubMed Web of Science ®Google Scholar
• Lin J, Tiong S, Chen C. Surface characterization and platelet adhesion studies on fluorocarbons prepared by plasma-induced graft polymerization J. Biomater. Sci. Polym.11, 701–714 (2000).
   PubMed Web of Science ®Google Scholar
• Liu TY, Lin WC, Huang LY, Chen SY, Yang MC. Surface characteristics and hemocompatibility of PAN/PVDF blend membranes. Polym. Adv. Technol.16(5), 413–419 (2005).
   Web of Science ®Google Scholar
• Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet370(9591), 937–948 (2007).
   PubMed Web of Science ®Google Scholar
• Morice MC, Colombo A, Meier B et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA295(8), 895–904 (2006).
   PubMed Web of Science ®Google Scholar
• Windecker S, Remondino A, Eberli FR et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N. Engl. J. Med.353(7), 653–662 (2005).
   PubMed Web of Science ®Google Scholar
• Park KW, Yoon JH, Kim JS et al. Efficacy of Xience/promus Versus Cypher in Reducing Late Loss After Stenting (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial. Am. Heart J.157(5), 811–817.e1 (2009).
   PubMedGoogle Scholar
• Rasmussen K, Maeng M, Kaltoft A et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet375(9720), 1090–1099 (2010).
   PubMed Web of Science ®Google Scholar
• Kandzari D. ENDEAVOR III: 5 year final outcomes. Presented at: The American College of Cardiology Scientific Sessions. Atlanta, GA, USA, 14–16 March 2010.
   Google Scholar
• Leon MB, Mauri L, Popma JJ et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the Taxus paclitaxel-eluting stent in de novo native coronary lesions 12 month outcomes from the ENDEAVOR IV trial. J. Am. Coll. Cardiol.55(6), 543–554 (2010).
   PubMed Web of Science ®Google Scholar
• Camenzind E, Wijns W, Mauri L et al. Rationale and Design of the Patient Related Outcomes with Endeavor Versus Cypher Stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am. Heart J.158(6), 902–909 e905 (2009).
   PubMedGoogle Scholar
• Meredith IT, Worthley S, Whitbourn R et al. The next-generation Endeavor Resolute stent: 4 month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention3(1), 50–53 (2007).
   PubMedGoogle Scholar
• Udipi K, Melder RJ, Chen M et al. The next generation endeavor resolute stent: role of the Bio-Linx Polymer System. EuroIntervention3(1), 137–139 (2007).
   PubMedGoogle Scholar
• Meredith IT, Worthley S, Whitbourn R et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC2(10), 977–985 (2009).
   PubMedGoogle Scholar
• Nikolsky E. Endeavor Resolute: clinical results to 36 months. Presented at: TCT Conference 2009. San-Francisco, CA, USA, 21–25 September 2009.
   Google Scholar
• Serruys PW, Silber S, Garg S et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N. Engl. J. Med.363(2), 136–146 (2010).
   PubMed Web of Science ®Google Scholar
• Costa JR Jr, Abizaid A, Feres F et al. EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions. EuroIntervention4(1), 53–58 (2008).
   PubMedGoogle Scholar
• Abizaid A. Single center, first in man study of the Elixir Novolimus eluting coronary stent system with durable polymer: 24 month clinical safety and efficacy results. Am. J. Cardiol.104, 158D (2009).
   PubMedGoogle Scholar
• Serruys PW, Garg S, Abizaid A et al. A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9 month follow-up results of the EXCELLA II study. EuroIntervention6(2), 195–205 (2010).
   PubMed Web of Science ®Google Scholar
• Rutsch W. Multi-center first-in-man study with the lowest known limus dose on the Elixir Medical myolimus eluting coronary stent system with a durable polymer: nine month clinical and six month angiographic and IVUS follow-up. Presented at: EuroPCR. Barcelona, Spain, 19–22 May 2009.
   Google Scholar
• Schofer J. Multicenter, first-in-man study of the Elixir Myolimus coronary stent system with bioabsorbable polymer: 12 month clinical and angiographic/IVUS results. Presented at: EuroPCR. Paris, France, 25–28 May 2010.
   Google Scholar
• Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation103(23), 2816–2821 (2001).
   PubMed Web of Science ®Google Scholar
• Pache J, Kastrati A, Mehilli J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J. Am. Coll. Cardiol.41(8), 1283–1288 (2003).
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Cannon LA, Feldman RL et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the Taxus Element Paclitaxel-Eluting Coronary Stent System) trial. J. Am. Coll. Cardiol.56(4), 264–271 (2010).
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ. Taxus PERSEUS: a novel platinum chromium, thin-strut Taxus Element stent for the treatment of de novo coronary stenoses. Presented at: i2 summit. American College of Cardiology. Atlanta, USA, 15 March 2010.
   Google Scholar
• Peled A, Kollet O, Ponomaryov T et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood95(11), 3289–3296 (2000).
   PubMed Web of Science ®Google Scholar
• Blindt R, Vogt F, Astafieva I et al. A-novel drug-eluting stent coated with an integrin-binding cyclic Arg–Gly–Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J. Am. Coll. Cardiol.47(9), 1786–1795 (2006).
   PubMed Web of Science ®Google Scholar
• Stefanadis C, Toutouzas K, Stefanadi E, Kolodgie F, Virmani R, Kipshidze N. First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: angiographic results in a rabbit atheromatic model. Hellenic. J. Cardiol.47(1), 7–10 (2006).
   PubMedGoogle Scholar
• Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation105(15), 1756–1759 (2002).
   PubMed Web of Science ®Google Scholar
• Pendyala L, Yin X, Li J et al. Polymer-free cerivastatin-eluting stent shows superior neointimal inhibition with preserved vasomotor function compared to polymer-based paclitaxel-eluting stent in rabbit iliac arteries. EuroIntervention6(1), 126–133 (2010).
   PubMedGoogle Scholar
• Basalus MW, Ankone MJ, van Houwelingen GK, de Man FH, von Birgelen C. Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. EuroIntervention5(1), 157–165 (2009).
   PubMed Web of Science ®Google Scholar
• Otsuka Y, Chronos NA, Apkarian RP, Robinson KA. Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents. J. Invasive Cardiol.19(2), 71–76 (2007).
   PubMedGoogle Scholar
• Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet372(9644), 1163–1173 (2008).
   PubMed Web of Science ®Google Scholar
• Serruys PW. BIOMATRIX: first report from the 3 year LEADERS trial. Presented at: Transcatheter Cardio-vascular Therapeutics 2010. Washington DC, USA, 21–25 September 2010.
   Google Scholar
• Garg S, Serruys PW. Coronary stents: looking forward. J. Am. Coll. Cardiol.56(Suppl. 10), S43–S78 (2010).
   PubMed Web of Science ®Google Scholar
• Hamilos MI, Ostojic M, Beleslin B et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J. Am. Coll. Cardiol.51(22), 2123–2129 (2008).
   PubMed Web of Science ®Google Scholar
• Chevalier B, Silber S, Park SJ et al. Randomized comparison of the NOBORI biolimus A9-eluting coronary stent with the Taxus libertè paclitaxel-eluting coronary stent in patients with stenosis in native coronary artery. Circ. Cardiovasc. Inter.2, 188–195 (2009).
   PubMed Web of Science ®Google Scholar
• Wessely R. New drug-eluting stent concepatients. Nat. Rev. Cardiol.7(4), 194–203 (2010).
   PubMed Web of Science ®Google Scholar
• Ormiston JA, Abizaid A, Spertus J et al. Six month results of the NEVO RES-ELUTION I (NEVO RES-I) trial: a randomized, multicenter comparison of the nevo sirolimus-eluting coronary stent with the Taxus liberte paclitaxel-eluting stent in de novo native coronary artery lesions. Circ. Cardiovasc. Interv.3(6), 556–564 (2010).
   PubMedGoogle Scholar
• Abizaid A. The NEVO RES Elution I study: a randomized multicenter comparison of the NEVO reservoir-based Sirolimus eluting-stent with the Taxus Libertè Paclitaxel-eluting stent: first presentation of the 12 month outcomes. Presented at: EuroPCR. Paris, France, 25–28 May 2010.
   Google Scholar
• Han Y, Jing Q, Xu B et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in ‘real-world’ practice: 18 month clinical and 9 month angiographic outcomes. JACC Cardiovasc. Interv.2(4), 303–309 (2009).
   PubMed Web of Science ®Google Scholar
• Chamie D, Costa JR Jr, Abizaid A et al. Serial angiography and intravascular ultrasound: results of the SISC Registry (Stents In Small Coronaries). JACC Cardiovasc. Interv.3(2), 191–202 (2010).
   PubMed Web of Science ®Google Scholar
• Botelho R. The Cardiomind Sparrow DES Program (CARE II): a bioabsorbable polymer sirolimus eluting ‘micro-stent’. Presented at: TCT Conference 2009. San-Francisco, CA, USA, 21–25 September 2009.
   Google Scholar
• Byrne RA, Kufner S, Tiroch K et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart95(18), 1489–1494 (2009).
   PubMed Web of Science ®Google Scholar
• Adriaenssens T, Mehilli J, Wessely R et al. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J. Am. Coll. Cardiol.49(12), 1265–1271 (2007).
   PubMed Web of Science ®Google Scholar
• Verheye S, Agostoni P, Dawkins KD et al. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with de novo Lesions of the Native Coronary Arteries) trial. JACC Cardiovasc. Interv.2(3), 205–214 (2009).
   PubMedGoogle Scholar
• Byrne RA, Mehilli J, Iijima R et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs polymer-based drug-eluting stents. Eur. Heart J.30(8), 923–931 (2009).
   PubMed Web of Science ®Google Scholar
• Byrne RA, Kastrati A, Tiroch K et al. 2 year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based cypher and endeavor, drug-eluting stents. J. Am. Coll. Cardiol.55, 2536–2543 (2010).
   PubMedGoogle Scholar
• Lee CW. CiloTaxTM Dual-drug eluting stent a prospective, randomized, controlled trial of a stent eluting cilostazol and paclitaxel. Presented at: TCT Conference 2009. San-Francisco, CA, USA, 21–25 September 2009.
   Google Scholar
• Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science275(5302), 964–967 (1997).
   PubMed Web of Science ®Google Scholar
• De Winter R, e-HEALING Registry. Can a pro-healing stent make a difference? final 12 month outcomes from the e-HEALING 5,000 patient registry using the EPC-Coated genous stent. Presented at: TCT Conference 2009. San-Francisco, CA, USA, 21–25 September 2009.
   Google Scholar
• Beijk MA, Klomp M, Verouden NJ et al. Genous™ endothelial progenitor cell capturing stent vs the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary reste-nosis: a randomized, single-centre, pilot study. Eur. Heart J.31(9), 1055–1064 (2009).
   PubMedGoogle Scholar
• Granada JF, Inami S, Aboodi MS et al. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ. Cardiovasc. Interv.3(3), 257–266 (2010).
   PubMed Web of Science ®Google Scholar
• Granada JF. The Orbus-neich EPC-coated bioabsorbable polymer sirolimus-eluting stent program. Presented at: Transcatheter Cardiovascular Therapeutics. San-Francisco, CA, USA, 21 September 2010.
   Google Scholar
• Tada N, Virmani R, Grant G et al. Polymer-free biolimus a9-coated stent demonstrates more sus-tained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ. Cardiovasc. Interv.3(2), 174–183 (2010).
   PubMed Web of Science ®Google Scholar
• Virmani R. Are polymer-free DES safer? Observations from experimental studies in animal models. Presented at: Transcatheter Therapeutics 2009. San-Francisco, CA, USA, 21–25 September 2009.
   Google Scholar
• Grube E. BioFreedom first in man progress report. A-prospective, randomized, non-inferiority trial comparing biolimus drug coated-polymer free stent ‘BioFreedom™’ versus paclitaxel-eluting stent with durable polymer ‘Taxus™ Liberté™’. 4 month cohort follow-up. Presented at: TCT Conference 2009. San Francisco, USA, 21–25 September 2009.
   Google Scholar
• Costa JR Jr, Abizaid A, Costa R et al. 1 year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC Cardiovasc. Interv.2(5), 422–427 (2009).
   PubMed Web of Science ®Google Scholar
• Tanguay JF, Zidar JP, Phillips HR 3rd, Stack RS. Current status of biodegradable stents. Cardiol. Clin.12(4), 699–713 (1994).
   PubMedGoogle Scholar
• Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet371(9616), 899–907 (2008).
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ormiston JA, Onuma Y et al. A-bioabsorbable everolimus-eluting coronary stent sys-tem (ABSORB): 2 year outcomes and results from multiple imaging methods. Lancet373(9667), 897–910 (2009).
   PubMed Web of Science ®Google Scholar
• Onuma Y. Three year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention6(4), 447–453 (2010).
   PubMed Web of Science ®Google Scholar
• Post MJ, de Graaf-Bos AN, van Zanten HG, de Groot PG, Sixma JJ, Borst C. Thrombogenicity of the human arterial wall after interventional thermal injury. J. Vasc. Res.33(2), 156–163 (1996).
   PubMedGoogle Scholar
• Yamawaki T, Shimokawa H, Kozai T et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J. Am. Coll. Cardiol.32(3), 780–786 (1998).
   PubMed Web of Science ®Google Scholar
• Ormiston J, Serruys PW. Bioabsorbable coronary stent. Cardiovasc. Inter.1(2), 255–260 (2009).
   Google Scholar
• Jabara R. Polyanhydride based on salicylic acid and adipic acid anhydride. Presented at: EuroPCR. Barcelona, Spain, 19–22 May 2009.
   Google Scholar
• Meredith IT, Ormiston J, Whitbourn R et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention1(2), 157–164 (2005).
   PubMedGoogle Scholar
• Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Cutlip DE. Five year clinical follow-up after implantation of the Endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human study. Catheter Cardiovasc. Interv.74(7), 989–995 (2009).
   PubMed Web of Science ®Google Scholar
• Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation114(8), 798–806 (2006).
   PubMed Web of Science ®Google Scholar
• Van Leeuwen F. Randomised trial comparing the ENDEAVOR zotarolimus-eluting stent and the driver bare metal stent in single de novo native coronary artery lesions: five year clinical follow-up of ENDEAVOR II. Presented at: EuroPCR. Barcelona, Spain, 19–22 May 2009.
   Google Scholar
• Kandzari DE, Leon MB, Popma JJ et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol.48(12), 2440–2447 (2006).
   PubMed Web of Science ®Google Scholar
• Eisenstein EL, Leon MB, Kandzari DE et al. Long-term clinical and economic analysis of the En-deavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3 year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in de novo Native Coronary Artery Lesions). JACC Cardiovasc. Interv.2(12), 1199–1207 (2009).
   PubMed Web of Science ®Google Scholar
• Leon MB. First Presentation of the ENDEAVOR IV 3 year results. Presented at: TCT Conference 2009. San-Francisco, CA, USA, 21–25 September 2009.
   Google Scholar
• Park DW, Kim YH, Yun SC et al. Comparison of zotarolimus-eluting stents with sirolimus- and pa-clitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J. Am. Coll. Cardiol.56(15), 1187–1195 (2010).
   PubMed Web of Science ®Google Scholar
• Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12 month data from the E-Five registry. JACC Cardiovasc. Interv.2(12), 1227–1235 (2009).
   PubMedGoogle Scholar
• Meredith IT. Real world outcomes in patients with coronary artery disease treated with the endeavor ZES: 2 year results from the E-Five registry. Presented at: EuroPCR. Barcelona, Spain, 19–22 May 2009.
   Google Scholar
• Wiemer M, Serruys PW, Miquel-Hebert K et al. Five year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheter. Cardiovasc. Interv.75(7), 997–1003 (2010).
   PubMed Web of Science ®Google Scholar
• Garg S, Serruys PW, Miquel-Hebert K. Four year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial. Catheter. Cardiovasc. Interv. DOI: 10.1002/ccd.22770 (2010) (Epub ahead of print).
   Google Scholar
• Stone G. The XIENCE V-PROMUS everolimus-eluting stent: comprehensive update of the clinical trial program. Presented at: Transcatheter Cardiovascular Therapeutics. San-Francisco, CA, USA, 21 September 2009.
   Google Scholar
• Stone G. SPIRIT IV: two year results from a prospective randomized trial of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease. Presented at: Transcatheter Cardiovascular Therapeutics. Washington, DC, USA, 21–25 September 2010.
   Google Scholar
• Chevalier B. SPIRIT V single arm study: 2 year follow-up. Presented at: EuroPCR. Paris, France, 25–28 May 2010.
   Google Scholar
• Smits P. COMPARE: two year results from a prospective randomized trial of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease. Presented at Transcatheter Cardiovascular Therapeutics. Washington, DC, USA, 21 September 2010.
   Google Scholar
• Jensen L. SORT OUT 4: a prospective randomized trial of everolimus-eluting stents and sirolimus-eluting stents in patients with coronary artery disease. Presented at: Transcatheter Cardiovascular Therapeutics. Washington, DC, USA, 21 September 2010.
   Google Scholar
• Byrne R. ISAR-TEST-4: two year clinical and angiographic outcomes from a prospective randomized trial of everolimus-eluting stents and sirolimus-eluting stents in patients with coronary artery disease. Presented at: Transcatheter Cardiovascular Therapeutics. Washington, DC, USA, 21 September 2010.
   Google Scholar
• Serruys P. RESOLUTE All-Comers trial: a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention. Primary results. Presented at: EuroPCR. Paris, France, 25–28 May 2010.
   Google Scholar
• Dawkins K. The Element stent technology. Presented at: EuroPCR. Paris, France, 25–28 May 2010.
   Google Scholar
• Grube E, Schofer J, Hauptmann KE et al. A-novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9 month outcomes with the JACTAX HD stent. JACC Cardiovasc. Interv.3(4), 431–438 (2009).
   Google Scholar
• Dani S, Kukreja N, Parikh P et al. Biodegradable-polymer-based, sirolimus-eluting supralimus stent: 6 month angiographic and 30 month clinical follow-up results from the series I prospective study. EuroIntervention4(1), 59–63 (2008).
   PubMedGoogle Scholar
• Vranckx P, Serruys PW, Gambhir S et al. Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9 month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. EuroIntervention2(3), 310–317 (2006).
   PubMedGoogle Scholar
• Onuma Y, Serruys P, den Heijer P et al. MAHOROBA, first-in-man study: 6 month results of a bio-degradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. Eur. Heart J.30(12), 1477–1485 (2009).
   PubMedGoogle Scholar
• Mehilli J, Kastrati A, Wessely R et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation113(2), 273–279 (2006).
   PubMed Web of Science ®Google Scholar
• Garg S, Serruys PW. Coronary stents: current status. J. Am. Coll. Cardiol.56(10 Suppl.), S1–42 (2010).
   PubMed Web of Science ®Google Scholar
• Spertus J. NEVO RES-Elution I QOL. Oral presentation. Presented at: TCT Conference 2009. San Francisco, CA, USA, 24 September 2009.
   Google Scholar
• Schülen H. The ISAR Polymer-free Single and Dual Drug-eluting stent Programs. Oral presentation. Presented at: TCT Conference 2009. San Francisco, CA, USA, 22 September 2009.
   Google Scholar
• Serruys PW. Futuristic…Bioabsorbable Drug-eluting Stents. Oral presentation. Presented at: TCT Conference 2009. San Francisco, CA, USA, 24 September 2009.
   Google Scholar